OP016: Mini-COMET: Safety and efficacy of ≥97 weeks’ avalglucosidase alfa in infantile-onset Pompe disease participants previously treated with alglucosidase alfaDavid Kronn, On behalf of the Mini-COMET investigators, Susan Sparks et al.|Genetics in Medicine|2022Cited by 10
The Mini-COMET Clinical Trial: Safety and Efficacy of Avalglucosidase Alfa after 97 Weeks of Treatment in Children with Infantile-Onset Pompe Disease Previously Treated with Alglucosidase AlfaDavid Kronn, James Davison, Alexander Broomfield et al.|The Journal of Pediatrics|2025Cited by 3
Mini-COMET study: Safety, biomarker, and efficacy data after avalglucosidase alfa dosing for ≥ 97 weeks in participants with infantile-onset pompe disease (IOPD) previously treated with alglucosidase alfa who had demonstrated clinical declineDavid Kronn, Priya S. Kishnani, James Davison et al.|Molecular Genetics and Metabolism|2022Cited by 1
Mini-COMET study: Effects of 97 weeks of avalglucosidase alfa dosing on ptosis in participants with infantile-onset Pompe disease who were previously treated with alglucosidase alfaPriya S. Kishnani, S. Grace Prakalapakorn, Marguerite C. Weinert et al.|Molecular Genetics and Metabolism|2023Cited by 0
Mini-COMET study: Safety and efficacy data after avalglucosidase alfa dosing for ≥ 145 weeks in participants with infantile-onset Pompe disease (IOPD) who had demonstrated clinical decline or sub-optimal response while receiving alglucosidase alfaDavid Kronn, Yin‐Hsiu Chien, Priya S. Kishnani et al.|Molecular Genetics and Metabolism|2024Cited by 0